Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleEndocrine and Diabetes

Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models

David R. Powell, Christopher M. DaCosta, Melinda Smith, Deon Doree, Angela Harris, Lindsey Buhring, William Heydorn, Amr Nouraldeen, Wendy Xiong, Padmaja Yalamanchili, Faika Mseeh, Alan Wilson, Melanie Shadoan, Brian Zambrowicz and Zhi-Ming Ding
Journal of Pharmacology and Experimental Therapeutics August 2014, 350 (2) 232-242; DOI: https://doi.org/10.1124/jpet.114.214304
David R. Powell
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher M. DaCosta
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melinda Smith
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deon Doree
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Harris
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsey Buhring
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Heydorn
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amr Nouraldeen
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Xiong
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Padmaja Yalamanchili
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faika Mseeh
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Wilson
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Shadoan
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Zambrowicz
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi-Ming Ding
Lexicon Pharmaceuticals, Inc., The Woodlands, Texas (D.R.P., C.M.D., M.Sm., D.D., A.H., L.B., A.N., W.X., F.M., A.W., M.Sh., B.Z., Z.-M.D.); and Lexicon Pharmaceuticals, Inc., Princeton, New Jersey (W.H., P.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Pharmacokinetic studies of LX4211 in three preclinical species. (A) Chemical structure of LX4211. Plasma concentrations of LX4211 (mean ± S.D.) were measured at various times after (B) an intravenous dose of 1 mg/kg to each species, and (C) an oral dose of 10 mg/kg to mice and rats, and an oral dose of 3 mg/kg to dogs.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    LX4211 increases UGE in mice, rats, and dogs. UGE was measured over 24-hour intervals as described in Materials and Methods. In (A) mice, (C) rats, and (E) dogs, UGE was measured during the first 24 hours after treatment with vehicle or increasing doses of LX4211. After animals received a single dose of LX4211 on day 1, UGE was also measured in (B) mice during three successive 24-hour intervals; (D) rats during two to four successive 24-hour intervals; and (F) dogs during two successive 24-hour intervals. (A, C, and E) *P < 0.05; **P < 0.01; ***P < 0.001 versus the vehicle-treated group.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    LX4211 improves glucose homeostasis in KKAy diabetic mice: study 1. (A) Schematic outline of study design. BG, fed blood glucose; BW, body weight; FC, food consumption; Ins, fed serum insulin; UGE, 24-hour UGE measured in metabolic cages. (B) A time course of change in A1C levels. (C) A time course of fed blood glucose levels. (D) Blood glucose excursions from the week 9 OGTT data. (E) Change in serum insulin levels between the 0- and 30-minute time points of the week 9 OGTT. (F) Total pancreatic insulin: at necropsy, the pancreas of each mouse was isolated, and pancreatic insulin was extracted and measured as described in Materials and Methods. (G) Multiple 24-hour UGE measurements were made on mice in metabolic cages both before and after the start of LX4211 dosing. (B–G) *P < 0.05; **P < 0.01; ***P < 0.001 versus the vehicle-treated group.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    LX4211 improves glucose homeostasis in KKAy diabetic mice: study 2. (A) Schematic outline of study design. BW, body weight; FC, food consumption; Fed G, fed serum glucose; UGE, 24-hour UGE measured in metabolic cages. (B) Change in A1C levels between baseline (week 2) and week 6 of the study. (C) Fed serum glucose levels obtained at necropsy. (D) Blood glucose excursions from the week 6 OGTT data. (E) Change in serum insulin levels between the 0- and 30-minute time points of the week 6 OGTT data. (F) Total pancreatic insulin: at necropsy, the pancreas of each mouse was isolated, and pancreatic insulin was extracted and measured as described in Materials and Methods. (G) The mean value of two 24-hour UGE measurements made on consecutive days in mice acclimatized in metabolic cages during study week 7 or 8. (H) Total GLP-1 levels measured at necropsy, 2 hours after a 2 g/kg oral glucose bolus. (B–H) *P < 0.05; **P < 0.01; ***P < 0.001 versus the vehicle-treated group.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    The effect of LX4211 on body composition and food consumption in KKAy diabetic mice. In KKAy study 1, mice were evaluated for (A) change in body weight between the start of LX4211 treatment and necropsy; (B) change in body fat between QMR measurements made in week 1 and week 9; and (C) food consumption, reported as the mean daily intake measured during the 8 days that the mice were maintained in metabolic cages while receiving LX4211 or vehicle. In KKAy study 2, mice were evaluated for (D) change in body weight between measurements made on the first day of LX4211 or vehicle treatment and on multiple days during the first 6 weeks of treatment; (E) body fat measured by QMR during study week 9; and (F) food consumption, reported as the mean daily intake during the first 6 weeks of treatment with LX4211 or vehicle. (F) **P < 0.01; ***P < 0.001 versus the vehicle-treated group.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Effects of LX4211 on body weight of lean rats and dogs. In rats, (A) change in body weight and (B) food consumption were measured during a 4-week toxicology study and then compared between the vehicle-treated group (N = 15) and pooled data from groups receiving LX4211 at doses of 10 (N = 10), 30 (N = 10), or 100 (N = 15) mg/kg per day. In dogs, (C) change in body weight and (D) food consumption were also measured during a 4-week toxicology study and then compared between the vehicle-treated group (N = 10) and pooled data from groups receiving LX4211 at doses of 30 (N = 6) or 100 (N = 10) mg/kg per day. In rats, (E) body weight and (F) food consumption were measured during a 13-week toxicology study and then compared between the vehicle-treated group (N = 15) and individual groups receiving LX4211 at doses of 3 (N = 10), 10 (N = 10), 30 (N = 15) or 100 (N = 15) mg/kg/d. The key for all groups in E and F is found in E. No statistically significant adverse effects of LX4211 treatment were observed at these doses in any of the three studies. (A–D) *P < 0.05; **P < 0.01; ***P < 0.001 versus the vehicle-treated group. (F) *P < 0.05 for vehicle versus all other groups; ^P < 0.05 for vehicle versus the 10, 30, and 100 mg/kg per day groups.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    Effects of LX4211 on OP-CD obese rats. (A) Schematic outline of study design. BW, body weight; FC, food consumption; UGE, 24-hour UGE measured in metabolic cages. (B) UGE, presented as mean 24-hour UGE values estimated from collections made on three consecutive days in metabolic cages. (C) Change in body weight between the start of LX4211 treatment and necropsy. (D) Body fat and (E) lean body mass, measured by QMR at the end of the study. (F) Food consumption, reported as the mean daily intake during the 25 days of treatment with LX4211 or vehicle. Cecal contents were isolated from fed rats at the time of necropsy and used to measure (G) cecal glucose, reported here as the total amount of glucose recovered, and (H) cecal pH, which represents a direct pH measurement of the cecal contents. (B–E, G, and H) *P < 0.05; ***P < 0.001 versus the vehicle-treated group.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    LX4211 inhibits SGLT-mediated glucose transport

    SpeciesSGLT1SGLT2
    IC50NIC50N
    nMnM
    Humana36 ± 991.8 ± 0.48
    Mouseb62 ± 2680.6 ± 0.28
    Rat104 ± 38110.5 ± 0.310
    Dog86 ± 1481.4 ± 0.58
    • IC50, concentration causing half-maximal inhibition; N, number of determinations.

    • ↵a Data are from Zambrowicz et al., 2012.

    • ↵b Data are from Powell et al., 2013b.

    • View popup
    TABLE 2

    Pharmacokinetic parameters after a 1 mg/kg i.v. dose of LX4211

    SpeciesNHalf-LifeAUC0–∞CLVss
    hnM*hml/min/kgl/kg
    Dog57.27 ± 1.398849 ± 17964.6 ± 0.91.98 ± 0.34
    Rat40.90 ± 0.091847 ± 13221.3 ± 1.51.40 ± 0.07
    Mouse41.39 ± 0.451940 ± 33120.6 ± 3.02.07 ± 0.14
    • CL, clearance; N, number of animals; Vss, volume at steady state.

    • View popup
    TABLE 3

    Pharmacokinetic parameters after a 3 or 10 mg/kg oral dose of LX4211

    SpeciesNDoseHalf-LifeTmaxCmaxAUC0–∞%F
    mg/kghhnMnM*h
    Dog537.38 ± 1.170.65 ± 0.342502 ± 32518775 ± 413271 ± 16
    Rat410ND3.00 ± 1.151116 ± 378NDND
    Mouse4106.52 ± 0.820.31 ± 0.134373 ± 40819079 ± 158098 ± 8
    • %F, % bioavailable; N, number of animals; ND, not determined.

Additional Files

  • Figures
  • Tables
  • Data Supplement

    Files in this Data Supplement:

    • Supplemental Tables - Table S1: Body composition of KKAy mice and OP-CD obese rats after long-term treatment with LX4211. Table S2: Body weight and food consumption of lean Sprague-Dawley rats treated with LX4211 for 13 weeks.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 350 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 350, Issue 2
1 Aug 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Citation Tools
Research ArticleEndocrine and Diabetes

Effect of LX4211 on Glucose Homeostasis and Body Composition

David R. Powell, Christopher M. DaCosta, Melinda Smith, Deon Doree, Angela Harris, Lindsey Buhring, William Heydorn, Amr Nouraldeen, Wendy Xiong, Padmaja Yalamanchili, Faika Mseeh, Alan Wilson, Melanie Shadoan, Brian Zambrowicz and Zhi-Ming Ding
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 232-242; DOI: https://doi.org/10.1124/jpet.114.214304

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleEndocrine and Diabetes

Effect of LX4211 on Glucose Homeostasis and Body Composition

David R. Powell, Christopher M. DaCosta, Melinda Smith, Deon Doree, Angela Harris, Lindsey Buhring, William Heydorn, Amr Nouraldeen, Wendy Xiong, Padmaja Yalamanchili, Faika Mseeh, Alan Wilson, Melanie Shadoan, Brian Zambrowicz and Zhi-Ming Ding
Journal of Pharmacology and Experimental Therapeutics August 1, 2014, 350 (2) 232-242; DOI: https://doi.org/10.1124/jpet.114.214304
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Vitamin E Blocks COX-2 and Decreases Cervical Resistance
  • E2 Exacerbates Myocardial Dysfunction in Diabetic Females
  • PDX Improves Hepatic Steatosis
Show more Endocrine and Diabetes

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics